Immunocore Holdings (IMCR) Interest Expenses (2021 - 2026)

Immunocore Holdings has reported Interest Expenses for 6 years, with the latest figure at $69.3 million in Q1 2026.

• Quarterly Interest Expenses rose 1276.86% year-over-year to $69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.3 million (up 191.96% YoY) and the FY2025 annual result came in at $200.1 million, up 117.07% from the prior year.
• Interest Expenses rose to $69.3 million in Q1 2026 per IMCR's latest filing, from $3.1 million in the prior quarter.
• Over five years, Interest Expenses peaked at $326.1 million in Q1 2024 and troughed at $1.2 million in Q1 2023.
• A 5-year average of $32.0 million and a median of $3.4 million in 2022 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 25990.48% in 2024, then slumped 98.46% in 2025.
• Over 5 years, Interest Expenses stood at $3.7 million in 2022, then slumped by 64.87% to $1.3 million in 2023, then soared by 673.72% to $10.1 million in 2024, then tumbled by 69.86% to $3.1 million in 2025, then soared by 2168.92% to $69.3 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $69.3 million, $3.1 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.